RGLSRegulus Therapeutics Inc.

Nasdaq regulusrx.com


$ 2.54 $ 0.05 (2.01 %)    

Thursday, 02-May-2024 09:53:28 EDT
QQQ $ 423.30 $ -1.94 (-0.46 %)
DIA $ 380.09 $ -1.43 (-0.37 %)
SPY $ 501.84 $ -2.56 (-0.51 %)
TLT $ 88.26 $ 0.07 (0.08 %)
GLD $ 212.05 $ -0.41 (-0.19 %)
$ 2.51
$ 2.49
$ 0.00 x 0
$ 0.00 x 0
$ 2.49 - $ 2.55
$ 1.08 - $ 3.79
562,897
na
47.59M
$ 0.85
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-21-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-23-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-10-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-10-2021 06-30-2021 10-Q
12 05-14-2021 03-31-2021 10-Q
13 03-09-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-13-2020 06-30-2020 10-Q
16 05-14-2020 03-31-2020 10-Q
17 03-12-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-08-2019 06-30-2019 10-Q
20 05-10-2019 03-31-2019 10-Q
21 03-18-2019 12-31-2018 10-K
22 11-09-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-08-2018 12-31-2017 10-K
26 11-08-2017 09-30-2017 10-Q
27 08-02-2017 06-30-2017 10-Q
28 05-05-2017 03-31-2017 10-Q
29 03-03-2017 12-31-2016 10-K
30 11-02-2016 09-30-2016 10-Q
31 08-03-2016 06-30-2016 10-Q
32 05-03-2016 03-31-2016 10-Q
33 02-23-2016 12-31-2015 10-K
34 11-06-2015 09-30-2015 10-Q
35 08-05-2015 06-30-2015 10-Q
36 05-08-2015 03-31-2015 10-Q
37 02-19-2015 12-31-2014 10-K
38 11-06-2014 09-30-2014 10-Q
39 08-07-2014 06-30-2014 10-Q
40 05-09-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-regulus-therapeutics-maintains-9-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Regulus Therapeutics (NASDAQ:RGLS) with a Buy and maintains $9...

 regulus-therapeutics-q4-eps-040-misses-039-estimate

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate o...

 canaccord-genuity-maintains-buy-on-regulus-therapeutics-lowers-price-target-to-11

Canaccord Genuity analyst Whitney Ijem maintains Regulus Therapeutics (NASDAQ:RGLS) with a Buy and lowers the price target f...

 leerink-partners-initiates-coverage-on-regulus-therapeutics-with-outperform-rating-announces-price-target-of-6

Leerink Partners analyst Joseph Schwartz initiates coverage on Regulus Therapeutics (NASDAQ:RGLS) with a Outperform rating a...

 hc-wainwright--co-reiterates-buy-on-regulus-therapeutics-maintains-9-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Regulus Therapeutics (NASDAQ:RGLS) with a Buy and maintains $9...

 why-limbach-holdings-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarte...

 wells-fargo-maintains-equal-weight-on-regulus-therapeutics-raises-price-target-to-3

Wells Fargo analyst Jim Birchenough maintains Regulus Therapeutics (NASDAQ:RGLS) with a Equal-Weight and raises the price ta...

 gold-down-over-1-clearone-shares-spike-higher

U.S. stocks traded higher toward the end of trading, with the S&P 500 index gaining over 1% on Tuesday. The Dow traded up ...

 why-asana-shares-are-trading-lower-by-11-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.

 nasdaq-surges-over-1-blade-air-mobility-shares-plummet

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1% on Tuesday. The Dow traded up 0....

 dow-gains-100-points-us-inflation-rate-rises-to-32-in-february

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 100 points on Tuesday. Following the market o...

Core News & Articles
Market-Moving News for March 12th
03/12/2024 12:43:25

ORCL: 14% | Oracle shares are trading higher after the company reported Q3 financial results. RGLS: 103% | Regulus Therapeutic...

 why-is-kidney-disease-focused-regulus-therapeutics-stock-trading-higher-on-tuesday

Regulus Therapeutics reports findings for RGLS8429 in ADPKD study—mechanistic dose response, encouraging biomarkers, and an ove...

 regulus-therapeutics-released-topline-data-from-the-second-cohort-of-patients-in-its-phase-1b-multiple-ascending-dose-trial-of-rgls8429-for-autosomal-dominant-polycystic-kidney-disease

Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses Encouraging exploratory result...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION